Jin Yang Pharmaceutical Co., Ltd. (KOSDAQ:007370)
South Korea
· Delayed Price · Currency is KRW 6,060.00
+60.00 (1.00%)
At close: Mar 24, 2025, 3:30 PM KST
Jin Yang Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 113,332 | 93,708 | 76,264 | 62,839 | 49,525 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 113,332 | 93,708 | 76,264 | 62,839 | 49,525 | Upgrade
|
| Revenue Growth (YoY) | 20.94% | 22.87% | 21.36% | 26.88% | 4.59% | Upgrade
|
| Cost of Revenue | 43,448 | 36,652 | 30,613 | 28,856 | 23,242 | Upgrade
|
| Gross Profit | 69,884 | 57,056 | 45,651 | 33,984 | 26,282 | Upgrade
|
| Selling, General & Admin | 59,052 | 46,381 | 33,981 | 27,965 | 24,282 | Upgrade
|
| Other Operating Expenses | 205.11 | 170.02 | 139.73 | 146.93 | 108.97 | Upgrade
|
| Operating Expenses | 58,175 | 48,374 | 34,513 | 27,020 | 22,022 | Upgrade
|
| Operating Income | 11,708 | 8,682 | 11,138 | 6,964 | 4,261 | Upgrade
|
| Interest Expense | -1,855 | -1,374 | -1,285 | -208.28 | -162.88 | Upgrade
|
| Interest & Investment Income | 481.5 | 1,472 | 356.59 | 16.99 | 68.29 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.38 | -1.69 | 3.53 | -0.2 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,439 | 937.36 | 839.11 | 3,913 | 387.95 | Upgrade
|
| EBT Excluding Unusual Items | 12,771 | 9,716 | 11,053 | 10,685 | 4,554 | Upgrade
|
| Gain (Loss) on Sale of Investments | 24,298 | 2,253 | 3,132 | 1,438 | 1,979 | Upgrade
|
| Gain (Loss) on Sale of Assets | -77.14 | 0.86 | 24.9 | 9.53 | 0.6 | Upgrade
|
| Asset Writedown | - | - | 325.53 | - | - | Upgrade
|
| Other Unusual Items | 62.21 | 210.2 | - | - | - | Upgrade
|
| Pretax Income | 37,054 | 12,180 | 14,535 | 12,132 | 6,533 | Upgrade
|
| Income Tax Expense | 7,360 | -160 | 2,227 | 2,594 | 1,305 | Upgrade
|
| Net Income | 29,694 | 12,340 | 12,308 | 9,538 | 5,229 | Upgrade
|
| Net Income to Common | 29,694 | 12,340 | 12,308 | 9,538 | 5,229 | Upgrade
|
| Net Income Growth | 140.63% | 0.26% | 29.05% | 82.41% | 217.50% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 12 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | 9.76% | -9.06% | 10.33% | 1.27% | -0.27% | Upgrade
|
| EPS (Basic) | 2692.00 | 1145.00 | 1115.00 | 853.00 | 468.00 | Upgrade
|
| EPS (Diluted) | 2383.00 | 1087.00 | 986.00 | 843.00 | 468.00 | Upgrade
|
| EPS Growth | 119.23% | 10.24% | 16.96% | 80.13% | 218.37% | Upgrade
|
| Free Cash Flow | -77,268 | 7,851 | 4,230 | -545.86 | 4,881 | Upgrade
|
| Free Cash Flow Per Share | -6200.88 | 691.58 | 338.84 | -48.25 | 436.92 | Upgrade
|
| Gross Margin | 61.66% | 60.89% | 59.86% | 54.08% | 53.07% | Upgrade
|
| Operating Margin | 10.33% | 9.26% | 14.61% | 11.08% | 8.60% | Upgrade
|
| Profit Margin | 26.20% | 13.17% | 16.14% | 15.18% | 10.56% | Upgrade
|
| Free Cash Flow Margin | -68.18% | 8.38% | 5.55% | -0.87% | 9.86% | Upgrade
|
| EBITDA | 13,733 | 11,337 | 13,429 | 9,117 | 6,308 | Upgrade
|
| EBITDA Margin | 12.12% | 12.10% | 17.61% | 14.51% | 12.74% | Upgrade
|
| D&A For EBITDA | 2,024 | 2,655 | 2,291 | 2,154 | 2,048 | Upgrade
|
| EBIT | 11,708 | 8,682 | 11,138 | 6,964 | 4,261 | Upgrade
|
| EBIT Margin | 10.33% | 9.26% | 14.61% | 11.08% | 8.60% | Upgrade
|
| Effective Tax Rate | 19.86% | - | 15.32% | 21.38% | 19.97% | Upgrade
|
| Advertising Expenses | 3,748 | 3,869 | 2,541 | 2,125 | 2,351 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.